<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00632</drugbank-id>
  <drugbank-id>APRD00933</drugbank-id>
  <name>Docosanol</name>
  <description>Docosanol is a drug used for topical treatment for recurrent herpes simplex labialis episodes (episodes of cold sores or fever blisters). A saturated 22-carbon aliphatic alcohol, docosanol exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol inhibits fusion between the plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication.</description>
  <cas-number>661-19-8</cas-number>
  <unii>9G1OE216XY</unii>
  <average-mass>326.6</average-mass>
  <monoisotopic-mass>326.354866094</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>For the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).</indication>
  <pharmacodynamics>Docosanol is a saturated 22-carbon aliphatic alcohol which exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol speeds the healing of cold sores and fever blisters on the face or lips. It also relieves the accompanying symptoms, including tingling, pain, burning, and itching. Docosanol cannot, however, prevent cold sores or fever blisters from appearing.</pharmacodynamics>
  <mechanism-of-action>Docosanol works by inhibiting fusion between the human cell plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication. Unlike other cold-sore antivirals, docosanol does not act directly on the virus, and as such it is unlikely it will produce drug resistant mutants of HSV.</mechanism-of-action>
  <toxicity>Symptoms of overdose include headache, abdominal pain, increased serum lipase, nausea, dyspepsia, dizziness, and hyperbilirubinemia.</toxicity>
  <metabolism/>
  <absorption>Topical absorption has been shown to be minimal under conditions reflecting normal clinical use.</absorption>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as fatty alcohols. These are aliphatic alcohols consisting of a chain of a least six carbon atoms.</description>
    <direct-parent>Fatty alcohols</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Lipids and lipid-like molecules</superclass>
    <class>Fatty Acyls</class>
    <subclass>Fatty alcohols</subclass>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Primary alcohols</alternative-parent>
    <substituent>Alcohol</substituent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Fatty alcohol</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Primary alcohol</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">1-Docosanol</synonym>
    <synonym language="english" coder="">Behenic alcohol</synonym>
    <synonym language="english" coder="">Behenyl alcohol</synonym>
    <synonym language="english" coder="iupac">Docosan-1-ol</synonym>
    <synonym language="english/french/german" coder="inn/usan">Docosanol</synonym>
    <synonym language="english" coder="">Docosyl alcohol</synonym>
    <synonym language="english" coder="">N-Docosanol</synonym>
  </synonyms>
  <products>
    <product>
      <name>Abreva</name>
      <labeller>A-S Medication Solutions</labeller>
      <ndc-id/>
      <ndc-product-code>50090-3476</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>100 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abreva</name>
      <labeller>GlaxoSmithKline Consumer Healthcare Holdings (US) LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0135-0200</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2010-03-19</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>100 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>NDA020941</fda-application-number>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Abreva</name>
      <labeller>Glaxosmithkline Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02245677</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-08-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>10 %</strength>
      <route>Topical</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Docosanol</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0591-2981</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>100 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA208754</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Docosanol</name>
      <labeller>Cardinal Health (Leader) 70000</labeller>
      <ndc-id/>
      <ndc-product-code>70000-0517</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-09-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>100 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA208754</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Docosanol</name>
      <labeller>Actavis Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0472-2981</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-05</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>100 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA208754</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Docosanol</name>
      <labeller>Chain Drug Consortium, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>68016-052</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-02</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>100 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA208754</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Docosanol</name>
      <labeller>Walgreens</labeller>
      <ndc-id/>
      <ndc-product-code>0363-2981</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-04-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>100 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA208754</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Docosanol</name>
      <labeller>AmerisourceBergen (Good Neighbor Pharmacy) 46122</labeller>
      <ndc-id/>
      <ndc-product-code>46122-624</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>100 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA208754</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Docosanol</name>
      <labeller>Strategic Sourcing Services LLC</labeller>
      <ndc-id/>
      <ndc-product-code>62011-0433</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>100 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA208754</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Docosanol</name>
      <labeller>EQUALINE (SuperValu)</labeller>
      <ndc-id/>
      <ndc-product-code>41163-722</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-10-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Cream</dosage-form>
      <strength>100 mg/1g</strength>
      <route>Topical</route>
      <fda-application-number>ANDA208754</fda-application-number>
      <generic>true</generic>
      <over-the-counter>true</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Blistex</name>
      <company>DDD</company>
    </international-brand>
    <international-brand>
      <name>Erazaban</name>
      <company>Healthcare</company>
    </international-brand>
    <international-brand>
      <name>Healip</name>
      <company>Aco Hud</company>
    </international-brand>
    <international-brand>
      <name>Lafrost</name>
      <company>Incepta</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Abreva</name>
      <ingredients>Docosanol</ingredients>
    </mixture>
    <mixture>
      <name>Abreva</name>
      <ingredients>Docosanol</ingredients>
    </mixture>
    <mixture>
      <name>Docosanol</name>
      <ingredients>Docosanol</ingredients>
    </mixture>
    <mixture>
      <name>Docosanol</name>
      <ingredients>Docosanol</ingredients>
    </mixture>
    <mixture>
      <name>Docosanol</name>
      <ingredients>Docosanol</ingredients>
    </mixture>
    <mixture>
      <name>Docosanol</name>
      <ingredients>Docosanol</ingredients>
    </mixture>
    <mixture>
      <name>Docosanol</name>
      <ingredients>Docosanol</ingredients>
    </mixture>
    <mixture>
      <name>Docosanol</name>
      <ingredients>Docosanol</ingredients>
    </mixture>
    <mixture>
      <name>Docosanol</name>
      <ingredients>Docosanol</ingredients>
    </mixture>
    <mixture>
      <name>Docosanol</name>
      <ingredients>Docosanol</ingredients>
    </mixture>
    <mixture>
      <name>Abreva</name>
      <ingredients>Docosanol</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>GlaxoSmithKline Inc.</name>
      <url>http://www.gsk.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Glaxosmithkline</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Abreva 10% cream</description>
      <cost currency="USD">7.57</cost>
      <unit>g</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antiviral Agents</category>
      <mesh-id>D000998</mesh-id>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Herpes simplex virus</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>10 %</strength>
    </dosage>
    <dosage>
      <form>Cream</form>
      <route>Topical</route>
      <strength>100 mg/1g</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="D06BB11">
      <level code="D06BB">Antivirals</level>
      <level code="D06B">CHEMOTHERAPEUTICS FOR TOPICAL USE</level>
      <level code="D06">ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>84:04.06</ahfs-code>
  </ahfs-codes>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00632.pdf?1265922811</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00632.pdf?1265922747</msds>
  <patents>
    <patent>
      <number>4874794</number>
      <country>United States</country>
      <approved>1989-10-17</approved>
      <expires>2014-04-28</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>5534554</number>
      <country>United States</country>
      <approved>1996-07-09</approved>
      <expires>2013-12-13</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2421026</number>
      <country>Canada</country>
      <approved>2005-02-15</approved>
      <expires>2022-10-15</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>2156063</number>
      <country>Canada</country>
      <approved>1999-06-29</approved>
      <expires>2019-06-29</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>9.31</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-7.2</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.96e-05 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>8.81</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>docosan-1-ol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>docosanol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>326.6</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>326.354866094</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>CCCCCCCCCCCCCCCCCCCCCCO</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C22H46O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C22H46O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23/h23H,2-22H2,1H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>NOPFSRXAKWQILS-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>20.23</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>104.95</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>47.27</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>20</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>16.84</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Melting Point</kind>
      <value>65-72 Â°C</value>
      <source/>
    </property>
    <property>
      <kind>logP</kind>
      <value>9</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>12720</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>31000</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>12620</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46508049</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>12100</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50239998</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA164749211</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001249</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Docosanol</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1200453</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/docosanol.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target>
      <id>BE0000594</id>
      <name>Envelope glycoprotein GP350</name>
      <organism>HHV-4</organism>
      <actions>
        <action>intercalation</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A5297</ref-id>
            <pubmed-id>20210688</pubmed-id>
            <citation>Treister NS, Woo SB: Topical n-docosanol for management of recurrent herpes labialis. Expert Opin Pharmacother. 2010 Apr;11(5):853-60. doi: 10.1517/14656561003691847.</citation>
          </article>
          <article>
            <ref-id>A5298</ref-id>
            <pubmed-id>15571473</pubmed-id>
            <citation>Leung DT, Sacks SL: Docosanol: a topical antiviral for herpes labialis. Expert Opin Pharmacother. 2004 Dec;5(12):2567-71.</citation>
          </article>
          <article>
            <ref-id>A5299</ref-id>
            <pubmed-id>9864049</pubmed-id>
            <citation>Pope LE, Marcelletti JF, Katz LR, Lin JY, Katz DH, Parish ML, Spear PG: The anti-herpes simplex virus activity of n-docosanol includes inhibition of the viral entry process. Antiviral Res. 1998 Dec;40(1-2):85-94.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="P03200" source="Swiss-Prot">
        <name>Envelope glycoprotein GP350</name>
        <general-function/>
        <specific-function>Initiates virion attachment to host B-lymphocyte cell, leading to virus entry. Acts by binding to host CR2 at the surface of B-lymphocytes, facilitating the binding of viral glycoprotein gp42 to HLA class II molecules. Attachment triggers virion-host membrane fusion and invasion of the host cell.</specific-function>
        <gene-name/>
        <locus/>
        <cellular-location>Virion membrane</cellular-location>
        <transmembrane-regions>861-881</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>5.42</theoretical-pi>
        <molecular-weight>94430.75</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="10377">HHV-4</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>V01555</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>1334868</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P03200</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>GP350_EBVB9</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>MA</synonym>
          <synonym>Membrane antigen</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0001185|Envelope glycoprotein GP350
MEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQ
LDLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEE
QQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLD
VTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVP
SGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQ
SNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTET
DFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVI
FSKAPESTTTSPTLNTTGFADPNTTTGLPSSTHVPTNLTAPASTGPTVSTADVTSPTPAG
TTSGASPVTPSPSPWDNGTESKAPDMTSSTSPVTTPTPNATSPTPAVTTPTPNATSPTPA
VTTPTPNATSPTLGKTSPTSAVTTPTPNATSPTLGKTSPTSAVTTPTPNATSPTLGKTSP
TSAVTTPTPNATGPTVGETSPQANATNHTLGGTSPTPVVTSQPKNATSAVTTGQHNITSS
STSSMSLRPSSNPETLSPSTSDNSTSHMPLLTSAHPTGGENITQVTPASISTHHVSTSSP
APRPGTTSQASGPGNSSTSTKPGEVNVTKGTPPQNATSPQAPSGQKTAVPTVTSTGGKAN
STTGGKHTTGHGARTSTEPTTDYGGDSTTPRPRYNATTYLPPSTSSKLRPRWTFTSPPVT
TAQATVPVPPTSQPRFSNLSMLVLQWASLAVLTLLLLLVMADCAFRRNLSTSHTYTTPPY
DDAETYV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010412|Envelope glycoprotein GP350
ATGGAGGCAGCCTTGCTTGTGTGTCAGTACACCATCCAGAGCCTGATCCATCTCACGGGT
GAAGATCCTGGTTTTTTCAATGTTGAGATTCCGGAATTCCCATTTTACCCCACATGCAAT
GTTTGCACGGCAGATGTCAATGTAACTATCAATTTCGATGTCGGGGGCAAAAAGCATCAA
CTTGATCTTGACTTTGGCCAGCTGACACCCCATACGAAGGCTGTCTACCAACCTCGAGGT
GCATTTGGTGGCTCAGAAAATGCCACCAATCTCTTTCTACTGGAGCTCCTTGGTGCAGGA
GAATTGGCTCTAACTATGCGGTCTAAGAAGCTTCCAATTAACGTCACCACCGGAGAGGAG
CAACAAGTAAGCCTGGAATCTGTAGATGTCTACTTTCAAGATGTGTTTGGAACCATGTGG
TGCCACCATGCAGAAATGCAAAACCCCGTGTACCTGATACCAGAAACAGTGCCATACATA
AAGTGGGATAACTGTAATTCTACCAATATAACGGCAGTAGTGAGGGCACAGGGGCTGGAT
GTCACGCTACCCTTAAGTTTGCCAACGTCAGCTCAAGACTCGAATTTCAGCGTAAAAACA
GAAATGCTCGGTAATGAGATAGATATTGAGTGTATTATGGAGGATGGCGAAATTTCACAA
GTTCTGCCCGGAGACAACAAATTTAACATCACCTGCAGTGGATACGAGAGCCATGTTCCC
AGCGGCGGAATTCTCACATCAACGAGTCCCGTGGCCACCCCAATACCTGGTACAGGGTAT
GCATACAGCCTGCGTCTGACACCACGTCCAGTGTCACGATTTCTTGGCAATAACAGTATC
CTGTACGTGTTTTACTCTGGGAATGGACCGAAGGCGAGCGGGGGAGATTACTGCATTCAG
TCCAACATTGTGTTCTCTGATGAGATTCCAGCTTCACAGGACATGCCGACAAACACCACA
GACATCACATATGTGGGTGACAATGCTACCTATTCAGTGCCAATGGTCACTTCTGAGGAC
GCAAACTCGCCAAATGTTACAGTGACTGCCTTTTGGGCCTGGCCAAACAACACTGAAACT
GACTTTAAGTGCAAATGGACTCTCACCTCGGGGACACCTTCGGGTTGTGAAAATATTTCT
GGTGCATTTGCGAGCAATCGGACATTTGACATTACTGTCTCGGGTCTTGGCACGGCCCCC
AAGACACTCATTATCACACGAACGGCTACCAATGCCACCACAACAACCCACAAGGTTATA
TTCTCCAAGGCACCCGAGAGCACCACCACCTCCCCTACCTTGAATACAACTGGATTTGCT
GATCCCAATACAACGACAGGTCTACCCAGCTCTACTCACGTGCCTACCAACCTCACCGCA
CCTGCAAGCACAGGCCCCACTGTATCCACCGCGGATGTCACCAGCCCAACACCAGCCGGC
ACAACGTCAGGCGCATCACCGGTGACACCAAGTCCATCTCCATGGGACAACGGCACAGAA
AGTAAGGCCCCCGACATGACCAGCTCCACCTCACCAGTGACTACCCCAACCCCAAATGCC
ACCAGCCCCACCCCAGCAGTGACTACCCCAACCCCAAATGCCACCAGCCCCACCCCAGCA
GTGACTACCCCAACCCCAAATGCCACCAGCCCCACCTTGGGAAAAACAAGTCCTACCTCA
GCAGTGACTACCCCAACCCCAAATGCCACCAGCCCCACCTTGGGAAAAACAAGCCCCACC
TCAGCAGTGACTACCCCAACCCCAAATGCCACCAGCCCCACCTTGGGAAAAACAAGCCCC
ACCTCAGCAGTGACTACCCCAACCCCAAATGCCACCGGCCCTACTGTGGGAGAAACAAGT
CCACAGGCAAATGCCACCAACCACACCTTAGGAGGAACAAGTCCCACCCCAGTAGTTACC
AGCCAACCAAAAAATGCAACCAGTGCTGTTACCACAGGCCAACATAACATAACTTCAAGT
TCAACCTCTTCCATGTCACTGAGACCCAGTTCAAACCCAGAGACACTCAGCCCCTCCACC
AGTGACAATTCAACGTCACATATGCCTTTACTAACCTCCGCTCACCCAACAGGTGGTGAA
AATATAACACAGGTGACACCAGCCTCTATCAGCACACATCATGTGTCCACCAGTTCGCCA
GCACCCCGCCCAGGCACCACCAGCCAAGCGTCAGGCCCTGGAAACAGTTCCACATCCACA
AAACCGGGGGAGGTTAATGTCACCAAAGGCACGCCCCCCCAAAATGCAACGTCGCCCCAG
GCCCCCAGTGGCCAAAAGACGGCGGTTCCCACGGTCACCTCAACAGGTGGAAAGGCCAAT
TCTACCACCGGTGGAAAGCACACCACAGGACATGGAGCCCGGACAAGTACAGAGCCCACC
ACAGATTACGGCGGTGATTCAACTACGCCAAGACCGAGATACAATGCGACCACCTATCTA
CCTCCCAGCACTTCTAGCAAACTGCGGCCCCGCTGGACTTTTACGAGCCCACCGGTTACC
ACAGCCCAAGCCACCGTGCCAGTCCCGCCAACGTCCCAGCCCAGATTCTCAAACCTCTCC
ATGCTAGTACTGCAGTGGGCCTCTCTGGCTGTGCTGACCCTTCTGCTGCTGCTGGTCATG
GCGGACTGCGCCTTTAGGCGTAACTTGTCTACATCCCATACCTACACCACCCCACCATAT
GATGACGCCGAGACCTATGTATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF05109</identifier>
            <name>Herpes_BLLF1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>host cell membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>viral envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>virion membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral life cycle</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target>
      <id>BE0000712</id>
      <name>Envelope glycoprotein GP340</name>
      <organism>HHV-4</organism>
      <actions>
        <action>intercalation</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
          <article>
            <ref-id>A5298</ref-id>
            <pubmed-id>15571473</pubmed-id>
            <citation>Leung DT, Sacks SL: Docosanol: a topical antiviral for herpes labialis. Expert Opin Pharmacother. 2004 Dec;5(12):2567-71.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P68344" source="Swiss-Prot">
        <name>Envelope glycoprotein GP340</name>
        <general-function/>
        <specific-function>Responsible for EBV binding to the CR2 receptor on human B-cells.</specific-function>
        <gene-name/>
        <locus/>
        <cellular-location>Virion membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.96</theoretical-pi>
        <molecular-weight>92387.715</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="10377">HHV-4</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L07922</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>291520</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P68344</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>VGP3_EBVP3</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>MA</synonym>
          <synonym>Membrane antigen</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010500|Envelope glycoprotein GP340
MEAALLVCQYTIQSLIQLTRDDPGFFNVEILEFPFYPACNVCTADVNATINFDVGGKKHK
LNLDFGLLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINITTGEE
QQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLD
VTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVP
SGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQ
SNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTET
DFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVI
FSKAPESTTTSPTLNTTGFAAPNTTTGLPSSTHVPTNLTAPASTGPTVSTADVTSPTPAG
TTSGASPVTPSPSPRDNGTESKAPDMTSPTSAVTTPTPNATSPTPAVTTPTPNATSPTLG
KTSPTSAVTTPTPNATSPTPAVTTPTPNATIPTLGKTSPTSAVTTPTPNATSPTVGETSP
QANTTNHTLGGTSSTPVVTSPPKNATSAVTTGQHNITSSSTSSMSLRPSSISETLSPSTS
DNSTSHMPLLTSAHPTGGENITQVTPASTSTHHVSTSSPAPRPGTTSQASGPGNSSTSTK
PGEVNVTKGTPPKNATSPQAPSGQKTAVPTVTSTGGKANSTTGGKHTTGHGARTSTEPTT
DYGGDSTTPRTRYNATTYLPPSTSSKLRPRWTFTSPPVTTAQATVPVPPTSQPRFSNLSM
LVLQWASLAVLTLLLLLVMADCAFRRNLSTSHTYTTPPYDDAETYV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0001419|2661 bp
TTATACATAGGTCTCGGCGTCATCATATGGTGGGGTGGTGTAGGTATGGGATGTCGACAA
GTTACGCCTGAAGGCGCAGTCCGCCATGACCAGCAGCAGCAGAAGGGTCAGCACCGCCAG
AGAGGCCCACTGCAGTACTAGCATGGAGAGGTTTGAGAATCTGGGCTGGGACGTTGGCGG
GACAGGCACGGTGGCTTGGGCTGTGGTAACCGGTGGGCTCGTAAAAGTCCAGCGGGGCCG
CAGTTTGCTAGAAGTGCTGGGAGGTAGATAGGTGGTCGCATTGTATCTCGTTCTTGGCGT
AGTTGAATCACCGCCGTAATCTGTGGTGGGCTCTGTACTTGTCCGGGCTCCATGTCCTGT
GGTGTGCTTTCCACCGGTGGTAGAATTGGCCTTTCCACCTGTTGAGGTGACCGTGGGAAC
CGCCGTCTTTTGGCCACTGGGGGCCTGGGGCGACGTTGCATTTTTGGGGGGCGTGCCTTT
GGTGACATTAACCTCCCCCGGTTTTGTGGATGTGGAACTGTTTCCAGGGCCTGACGCTTG
GCTGGTGGTGCCTGGGCGGGGCGCTGGCGAACTGGTGGACACATGATGTGTGCTGGTAGA
GGCTGGTGTCACCTGTGTTATATTTTCACCACCTGTTGGGTGAGCGGAGGTTAGTAAAGG
CATATGTGACGTTGAATTGTCACTGGTGGAGGGGCTGAGTGTCTCTGAGATTGAACTGGG
TCTCAGTGACATGGAAGAGGTTGAACTTGAAGTTATGTTATGTTGGCCTGTGGTAACAGC
ACTGGTTGCATTTTTTGGTGGGCTGGTAACTACTGGGGTGGAACTTGTTCCTCCTAATGT
GTGGTTGGTGGTATTTGCCTGTGGACTTGTTTCTCCCACAGTAGGGCTGGTGGCATTTGG
GGTTGGGGTAGTCACTGCTGAGGTGGGACTTGTTTTTCCCAAGGTGGGGATGGTGGCATT
TGGGGTTGGGGTAGTCACTGCTGGGGTGGGGCTGGTGGCATTTGGGGTTGGGGTAGTCAC
TGCTGAGGTGGGACTTGTTTTTCCCAAGGTGGGGCTGGTGGCATTTGGGGTTGGGGTAGT
CACTGCTGGGGTGGGGCTGGTGGCATTTGGGGTTGGGGTAGTCACTGCTGAGGTGGGGCT
GGTCATGTCGGGGGCCTTACTTTCTGTGCCGTTGTCCCGTGGAGATGGACTTGGTGTCAC
CGGTGATGCGCCTGACGTTGTGCCGGCTGGTGTTGGGCTGGTGACATCCGCGGTGGATAC
AGTGGGGCCTGTGCTTGCAGGTGCGGTGAGGTTGGTAGGCACGTGAGTAGAGCTGGGTAG
ACCTGTCGTTGTATTGGGAGCAGCAAATCCAGTTGTATTCAAGGTAGGGGAGGTGGTGGT
GCTCTCGGGTGCCTTGGAGAATATAACCTTGTGGGTTGTTGTGGTGGCATTGGTAGCCGT
TCGTGTGATAATGAGTGTCTTGGGGGCCGTGCCAAGACCCGAGACAGTAATGTCAAATGT
CCGATTGCTCGCAAATGCACCAGAAATATTTTCACAACCCGAAGGTGTCCCCGAGGTGAG
AGTCCATTTGCACTTAAAGTCAGTTTCAGTGTTGTTTGGCCAGGCCCAAAAGGCAGTCAC
TGTAACATTTGGCGAGTTTGCGTCCTCAGAAGTGACCATTGGCACTGAATAGGTAGCATT
GTCACCCACATATGTGATGTCTGTGGTGTTTGTCGGCATGTCCTGTGAAGCTGGAATCTC
ATCAGAGAACACAATGTTGGACTGAATGCAGTAATCTCCCCCGCTCGCCTTCGGTCCATT
CCCAGAGTAAAACACGTACAGTATACTGTTATTGCCAAGAAATCGTGACACTGGACGTGG
TGTCAGACGCAGGCTGTATGCATACCCTGTACCAGGTATTGGGGTGGCCACGGGACTCGT
TGATGTGAGAATTCCGCCGCTGGGAACATGGCTCTCGTATCCACTGCAGGTGATGTTAAA
TTTGTTGTCTCCGGGCAGAACTTGTGAAATTTCGCCATCCTCCATAATACACTCAATATC
TATCTCATTACCGAGCATTTCTGTTTTTACGCTGAAATTCGAGTCTTGAGCTGATGTTGG
CAAACTTAAGGGTAGCGTGACATCCAGCCCCTGTGCCCTTACTACTGCCGTTATATTGGT
AGAATTACAGTTATCCCACTTTATGTATGGCACTGTTTCTGGTATTAGGTATACTGGGTT
TTGCATTTCTGCATGGTGGCACCACATGGTGCCAAACACATCTTGAAAGTAGACATCTAC
AGATTCCAGGCTTACTTGTTGCTCCTCTCCGGTGGTGATGTTAATTGGAAGCTTCTTAGA
CCGCATAGTTAGAGCCAATTCTCCTGCACCAAGGAGCTCCAGTAGAAAGAGATTGGTGGC
ATTTTCTGAGCCACCAAATGCACCTCGAGGTTGGTAGACAGCCTTTGTATGGGGTGTCAG
CAGGCCAAAGTCAAGATTAAGTTTATGCTTTTTGCCCCCGACATCGAAATTGATAGTTGC
ATTGACATCTGCCGTGCAAACATTGCACGCTGGGTAAAATGGGAATTCCAGAATCTCAAC
ATTGAAAAAACCAGGATCATCACGCGTGAGTTGGATAAGGCTCTGGATGGTGTACTGACA
CACAAGCAAGGCTGCCTCCAT</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF05109</identifier>
            <name>Herpes_BLLF1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>viral envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>virion membrane</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>viral life cycle</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>